Fujimoto S
First Department of Surgery, School of Medicine, Chiba University, Japan.
Nihon Geka Gakkai Zasshi. 1989 Sep;90(9):1447-50.
Immunochemotherapy using the antitumor polysaccharide Sizofiran (SPG), an extract from the culture broth of Schizophyllum, was prescribed randomly for unresectable or resectable gastric cancer patients. In case of unresectable cases, the SPG group (treated by SPG plus tegafur--F method--or 5-FU combined with MMC--MF method--) survived longer (p = 0.009 in the MF method and p = 0.003 in the F method) than did the control group (chemotherapy only). Concerning a treatment regimen for resectable cases, all patients were given 0.4mg/kg and 0.2mg/kg of MMC on the day of surgery and the next day, respectively. Oral tegafur was initiated on the 14th postoperative day and was continued as long as possible. In the SPG group, SPG was administered intramuscularly 40mg/week concurrently with the start of oral tegafur and was continued as long as possible. Although the overall survival rates for 5 years did not differ between both groups, the 5-year survival rate for stage III in the SPG group was superior to the findings for stage III in the control (p = 0.0105).
对于无法切除或可切除的胃癌患者，随机采用使用抗肿瘤多糖裂褶菌多糖（SPG）（裂褶菌培养液提取物）的免疫化疗。在无法切除的病例中，SPG组（采用SPG加替加氟-F法或5-氟尿嘧啶联合丝裂霉素-MF法治疗）的生存期比对照组（仅进行化疗）更长（MF法中p = 0.009，F法中p = 0.003）。关于可切除病例的治疗方案，所有患者在手术当天和第二天分别给予0.4mg/kg和0.2mg/kg的丝裂霉素。术后第14天开始口服替加氟，并尽可能持续服用。在SPG组中，从口服替加氟开始同时每周肌肉注射40mg的SPG，并尽可能持续使用。尽管两组的5年总生存率没有差异，但SPG组III期的5年生存率优于对照组III期的结果（p = 0.0105）。
